EC Number   |
Application |
Reference |
|---|
    4.2.3.17 | drug development |
cancer therapy, taxadiene is the precursor of paclitaxel, a chemotherapeutic agents |
693993 |
| 4.2.3.17 | drug development |
paclitaxel is a successful anticancer drug |
687790 |
| 4.2.3.17 | medicine |
chemotherapeutic agent against a range of cancers, including ovarian and breast cancer |
492232, 492233, 492234, 492235, 492236, 492237, 492238 |
| 4.2.3.17 | medicine |
taxanes can be used in cancer treatment |
682942 |
| 4.2.3.17 | synthesis |
constitutive expression in Nicotiana benthamiana leads to de novo production of taxadiene. Transformed homozygous lines produce 11-27 microg taxadiene/g of dry weight. Treatment with an elicitor, methyl jasmonate, and metabolic pathway shunting by suppression of the phytoene synthase gene expression results in increased taxadiene accumulation by 1.4- or 1.9fold, respectively |
730596 |
| 4.2.3.17 | synthesis |
taxadiene synthase ist he rate-limiting enzyme in the biosynthesis of the anticancer compound paclitaxel |
747344 |
| 4.2.3.17 | synthesis |
transformation of the roots of cultured Panax ginseng C.A. Meyer to produce taxadiene. Without any change in phenotypes or growth difference, a taxadiene synthase-transgenic ginseng line accumulates 9.1 microg taxadiene per gram of dry weight. In response to the treatment of methyl jasmonate for 3 or 6 days, the accumulation is 14.6 and 15.9 microg per g of dry weight, respectively |
729487 |
